Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;15(3):381-393.
doi: 10.1007/s11739-019-02270-6. Epub 2020 Jan 9.

Biomarkers of vascular disease in diabetes: the adipose-immune system cross talk

Affiliations
Review

Biomarkers of vascular disease in diabetes: the adipose-immune system cross talk

Federico Biscetti et al. Intern Emerg Med. 2020 Apr.

Abstract

Experimental and clinical studies aimed at investigating the mechanism(s) underlying vascular complications of diabetes indicate that a great number of molecules are involved in the pathogenesis of these complications. Most of these molecules are inflammatory mediators or markers generated by immune or adipose tissue. Some of them, i.e. resistin and sortilin, have been shown to be involved in the cross talk between adipocytes and inflammatory cells. This interaction is an attractive area of research, particularly in type 2 diabetes and obesity. Other proteins, such as adiponectin and visfatin, appear to be more promising as possible vascular markers. In addition, some molecules involved in calcium/phosphorus metabolism, such as klotho and FGF23, have an involvement in the pathogenesis of diabetic vasculopathy, which appears to be dependent on the degree of vascular impairment. Inflammatory markers are a promising tool for treatment decisions while measuring plasma levels of adipokines, sortilin, Klotho and FGF23 in adequately sized longitudinal studies is expected to allow a more precise characterization of diabetic vascular disease and the optimal use of personalized treatment strategies.

Keywords: Atherosclerosis; Biomarkers; Diabetes; Vascular complications.

PubMed Disclaimer

References

    1. Acta Med Okayama. 2014;68(3):157-62 - PubMed
    1. Circulation. 2004 Aug 10;110(6):738-43 - PubMed
    1. Circulation. 2001 Sep 18;104(12 Suppl 1):I308-I3 - PubMed
    1. Cardiovasc Res. 2016 May 1;110(1):118-28 - PubMed
    1. Circ Res. 2015 Feb 27;116(5):789-96 - PubMed

MeSH terms

LinkOut - more resources